The DOI matches its Crossref record.
Management of Patients With Treatment-Resistant Depression
Abstract
Antidepressant side effects may have implications with regard to patient safety as well as the overall tolerability of treatment. Side effects relevant to patient safety can contribute to an increased risk of morbidity and mortality, but may or may not result in patient distress or discomfort. In contrast, side effects related to tolerability can contribute to patient discomfort but are not associated with an immediate increase in risk of morbidity or mortality. Common tolerability-related side effects of modern antidepressants include nausea, insomnia, somnolence, fatigue, sexual dysfunction, and weight gain. Because these side effects can result in patient discomfort and distress, they can lead to poor compliance or noncompliance with treatment that, in turn, may result in an increased risk of depressive relapse or recurrence. Modern antidepressants have varying tolerability profiles, and clinicians should be vigilant about balancing treatment efficacy with side effects when choosing antidepressants. This article compares the rates of common tolerability-related side effects among the newer (post-tricyclic era) antidepressants with the selective serotonin reuptake inhibitors, the most popular contemporary first-line treatment for depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development
de Bodinat, C., Guardiola-Lemaitre, B., Mocaër, E., Renard, P., Muñoz, C., & Millan, M. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3140 · Cited by 593
Sarris, J., Panossian, A., Schweitzer, I., Stough, C., & Scholey, A. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.04.002 · Cited by 469
Mutz, J., Vipulananthan, V., Carter, B., Hurlemann, R., Fu, C. H. Y., & Young, A. H. (2019) · BMJ · doi:10.1136/bmj.l1079 · Cited by 427
Sexual Dysfunction, Depression, and the Impact of Antidepressants
Kennedy, S. H., & Rizvi, S. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31819c76e9 · Cited by 338
A systematic review of insomnia and complementary medicine
Sarris, J., & Byrne, G. J. (2011) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2010.04.001 · Cited by 328
Bai, S., Guo, W., Feng, Y., Deng, H., Li, G., Nie, H., Guo, G., Yu, H., Ma, Y., Wang, J., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-320912 · Cited by 235
The efficacy of exercise in reducing depressive symptoms among cancer survivors: a meta-analysis
Brown, J. C., Huedo-Medina, T. B., Pescatello, L. S., Ryan, S. M., Pescatello, S. M., Moker, E., LaCroix, J. M., Ferrer, R. A., & Johnson, B. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030955 · Cited by 201
Stratified medicine for mental disorders
Schumann, G., Binder, E. B., Holte, A., de Kloet, E. R., Oedegaard, K. J., Robbins, T. W., Walker-Tilley, T. R., Bitter, I., Brown, V. J., Buitelaar, J., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.09.010 · Cited by 186
Kautzky, A., Dold, M., Bartova, L., Spies, M., Kranz, G. S., Souery, D., Montgomery, S., Mendlewicz, J., Zohar, J., Fabbri, C., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12959 · Cited by 148
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
Difficult-to-treat depression: A clinical and research roadmap for when remission is elusive
Rush, A. J., Aaronson, S. T., & Demyttenaere, K. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418808585 · Cited by 120
Blumberger, D. M., Mulsant, B. H., Fitzgerald, P. B., Rajji, T. K., Ravindran, A. V., Young, L. T., Levinson, A. J., & Daskalakis, Z. J. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.579163 · Cited by 118
Ghajar, A., Neishabouri, S., Velayati, N., Jahangard, L., Matinnia, N., Haghighi, M., Ghaleiha, A., Afarideh, M., Salimi, S., Meysamie, A., et al. (2017) · Pharmacopsychiatry · doi:10.1055/s-0042-116159 · Cited by 110
Oliver, G., Dean, O., Camfield, D., Blair-West, S., Ng, C., Berk, M., & Sarris, J. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.1.12 · Cited by 96
Ketamine and the Future of Rapid-Acting Antidepressants
Riggs, L. M., & Gould, T. D. (2021) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-072120-014126 · Cited by 87
Mathews, M., Gommoll, C., Chen, D., Nunez, R., & Khan, A. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000057 · Cited by 77
Maneeton, N., Maneeton, B., Srisurapanont, M., & Martin, S. D. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2011.02264.x · Cited by 60
Maneeton, N., Maneeton, B., Srisurapanont, M., & Martin, S. D. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-160 · Cited by 51
Moving pharmacoepigenetics tools for depression toward clinical use
Hack, L. M., Fries, G. R., Eyre, H. A., Bousman, C. A., Singh, A. B., Quevedo, J., John, V. P., Baune, B. T., & Dunlop, B. W. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.02.009 · Cited by 33
Walter, K. H., Otis, N. P., Ray, T. N., Glassman, L. H., Beltran, J. L., Kobayashi Elliott, K. T., & Michalewicz-Kragh, B. (2023) · BMC Psychiatry · doi:10.1186/s12888-022-04452-7 · Cited by 33
Maneeton, B., Maneeton, N., Intaprasert, S., & Wootiluk, P. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s62714 · Cited by 27
Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD
Maneeton, B., Maneeton, N., Suttajit, S., Reungyos, J., Srisurapanont, M., & Martin, S. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s68393 · Cited by 30
Maneeton, N., Maneeton, B., Likhitsatian, S., Suttajit, S., Narkpongphun, A., Srisurapanont, M., & Woottiluk, P. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s79071 · Cited by 27
Ginsberg, L. D. (2009) · CNS Spectrums · doi:10.1017/s1092852900026353 · Cited by 19
Maneeton, N., Woottiluk, P., Suttajit, S., Likhitsathian, S., Charnsil, C., Srisurapanont, M., & Maneeton, B. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s91765 · Cited by 12
Metadata
- Authors
- Thase, M. E.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2008-03-15
- Volume
- 69
- Issue
- 3
- Pages
- e08
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2081500918
- Cited by
- 158
- References
- 0
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.